Ultrasound-assisted, Catheter-directed Thrombolysis for Acute Intermediate-high-risk Pulmonary Embolism
Italy180 participantsStarted 2022-11-28
Plain-language summary
The purpose of this retrospective and prospective multicenter study is to evaluate the incidence of pulmonary hypertension (PH) within 6 months from ultrasound-assisted, Catheter-directed Thrombolysis for acute intermediate- high-risk Pulmonary Embolism
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria
* Patients admitted with acute intermediate-high risk PE, defined according to ESC guidelines
* Symptoms onset within previous 14 days associated or not with deep venous thrombosis
* Confirmation of the PE by contrast-enhanced computed tomography of the chest with embolus located in at least one main or proximal lower lobe pulmonary artery
* Echocardiographic parameters of RV disfunction
* Patients with high-risk PE or hemodynamic deterioration on anticoagulation, who have absolute contraindications (high bleeding risk) to systemic thrombolysis and symptoms onset during the last 14 days. Patients with surgery-related embolic complications are also included (within 48 hours).
Exclusion Criteria
* Age \< 18 years old
* Patients unable to give informed consent
* Pregnancy
* Patients received fibrinolytic drugs in the preceding 4 days
* Bleeding diathesis
* Known bleeding disorder
* Low platelet count (\< 100.000/uL
* Gastrointestinal bleeding in the preceding 3 month
* Any ongoing known presence of malignant neoplasia months
* Advanced chronic kidney disease (defined as 11.000/uL)
* Gastrointestinal bleeding in the preceding 3 month
* Any ongoing known presence of malignant neoplasia at admission with survival rate \< 6
* Advanced chronic kidney disease (defined as eGFR \< 30 ml/min or on dialysis)